| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -16,692,668 | -13,205,053 |
| Proceeds from issuance of common stock, net | 21,427,151 | 19,783,423 |
| Net cash provided by financing activities | 21,427,151 | 19,783,423 |
| Net increase in cash and cash equivalents | 4,734,483 | 6,578,370 |
| Cash and cash equivalents at beginning of period | 10,551,916 | - |
| Cash and cash equivalents at end of period | 15,286,399 | - |
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)